Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Roche subsidiary Chugai submits approval application for Vamikibart in Japan

Chugai has submitted an approval application in Japan for Vamikibart to treat uveitic macular edema (UME). If approved, Vamikibart would be the first anti-IL-6 antibody therapy for this form of UME in Japan. The drug received orphan drug designation at the end of June. » Mais em finanzen.net
Chugai applies for additional approval for Tecentriq in Japan after positive Phase III result

Roche subsidiary Chugai has applied in Japan for approval of Tecentriq as adjuvant treatment for adults and children with a genetically defined form of colorectal cancer. The application is based on the international Phase III ATOMIC trial, which after three years showed a recurrence‑free rate of 86.3% in patients who received Tecentriq in addition to standard chemotherapy. Roche shares were slightly weaker in early trading. » Mais em finanzen.net
Japan approves Avastin from Chugai Pharmaceutical for treatment of neurofibromatosis type 2

The Japanese government has become the first in the world to approve Avastin (bevacizumab) from Chugai Pharmaceutical for therapeutic use in neurofibromatosis type 2 (NF2). NF2 is an incurable genetic disorder that causes bilateral tumors on the auditory nerves, leading to hearing loss and dizziness, and affects about 800 patients in Japan. Until now there was no effective drug for NF2; Avastin was developed by parent company Roche and has so far mainly been used as a cancer treatment. » Mais em finanzen.net

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, Chugai Pharmaceutical já distribuiu € 1,15 em dividendos. A última distribuição ocorreu em agosto.

Dados financeiros da empresa

No último trimestre, Chugai Pharmaceutical registou receitas de € 1,84 bi e um ganho líquido de € 626,71 mi

(EUR)	junho de 2026	YoY
Receitas	1,84 bi	7,56%
Ganho bruto	1,28 bi	7,61%
Ganho líquido	626,71 mi	9,34%
EBITDA	865,03 mi	7,49%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 59,31 bi
Número de ações	1,65 bi
Máximo/mínimo de 52 semanas	€ 60,04 - € 35,07
Rentabilidade de dividendos	3,19%
Dividendos TTM	€ 1,15
Beta	0,55
PER (PE Ratio)	22,42
PEG (PEG Ratio)	1,17
P/VC (PB Ratio)	5,21
P/V (PS Ratio)	7,87

Perfil da empresa

Chugai Pharmaceutical Co., Ltd. ist zusammen mit seinen Tochtergesellschaften in der Forschung, Entwicklung, Herstellung, dem Verkauf, Import und Export von Arzneimitteln in Japan und international tätig. Zu den Produkten des Unternehmens für die Onkologie gehören in erster Linie Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva und Xeloda; für die Osteoporose Actemra, Edirol und Bonviva; für Nierenerkrankungen Mircera und Oxarol; und für Neurologie und andere Krankheiten Hemlibra, CellCept und Enspryng. Das Unternehmen hat verschiedene Produktkandidaten in den Bereichen Onkologie, Knochen- und Gelenkerkrankungen, Autoimmunerkrankungen, Nierenerkrankungen, Neurologie und andere Krankheiten in der Entwicklung. Chugai Pharmaceutical Co., Ltd. unterhält strategische Allianzen mit der Roche-Gruppe sowie Kooperationen und gemeinsame Forschung mit Hochschulen. Das Unternehmen wurde 1925 gegründet und hat seinen Hauptsitz in Tokio, Japan. Chugai Pharmaceutical Co., Ltd. ist eine Tochtergesellschaft der Roche Holding Ltd.

Nome	Chugai Pharmaceutical
CEO	Osamu Okuda
Sede	Tokyo, sh Japão
Site	chugai-pharm.co.jp
Setor	Cuidados de saúde
Indústria	Biotecnologia
Entrada em bolsa	04/01/2000
Colaboradores	5.104